Celsius Therapeutics’ lead drug is for inflammatory bowel disease and has completed a Phase 1 trial.
Hannah Green
Source link
AbbVie pays $250 million to acquire Celsius Therapeutics
Celsius Therapeutics’ lead drug is for inflammatory bowel disease and has completed a Phase 1 trial.
Hannah Green
Source link
